Results 211 to 220 of about 95,261 (258)

Dimethyl fumarate abrogates hepatocellular carcinoma growth by inhibiting Nrf2/Bcl-xL axis and enhances sorafenib's efficacy. [PDF]

Sci Rep
Faleti OD, Alsaadawe M, Long J, Luo Q, Hu L, Zhang Y, Deng S, Wu G, Fang W, He M, Lyu X.   +10 more
europepmc   +1 more source

Platelet aging and desialylation increase apoptotic priming and BCL-X_L dependence. [PDF]

Cell Death Dis
Grozovsky R, Fraser CS, Qin X, Spetz J, Sarosiek KA.   +4 more
europepmc   +1 more source

Dual Targeting of Aurora-A and Bcl-xL Synergistically Reshapes the Immune Microenvironment and Induces Apoptosis in Breast Cancer. [PDF]

Cancer Sci
Liu M, Guo J, Liu W, Yang Z, Yu F.
europepmc   +1 more source

Bcl-2 and Bcl-xL in Diabetes: Contributions to Endocrine Pancreas Viability and Function. [PDF]

Biomedicines
Perez-Serna AA, Guzman-Llorens D, Dos Santos RS, Marroqui L.   +3 more
europepmc   +1 more source

Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models. [PDF]

Blood Adv
Kannan S, Li Y, Baran N, Yang X, Ghotbaldini S, Zhang Tatarata Q, Yoshimura S, Li Z, Hsiao Y, Balachander S, Andersen CL, Cidado J, Yu J, Jain N, Yang JJ, Konopleva M.   +15 more
europepmc   +1 more source

BCL-XL as a tumour prognostic factor?

Współczesna Onkologia, 2010
Bożenna Kaczmarek-Borowska, Szymon Zmorzyński, Agata Filip, Jacek Wojcierowski   +3 more
openaire   +1 more source

Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition

Radic-Sarikas B, Markovic M, Sturtzel C, Ilg M, Zylka MM, Surdez D, Metzelder M, Distel M, Ovsianikov A, Halbritter F, Kovar H.   +10 more
europepmc   +1 more source

Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors. [PDF]

Mol Cancer
Senent Y, Fresquet V, Jiménez V, Valencia K, Exposito F, Martín-Úriz PS, Camps G, Fernández-Pierola E, de Córdoba BR, González-Huarriz M, Tamayo I, Remírez A, Moreno H, Serrano D, Ajona D, Alonso MM, Lecanda F, Pineda-Lucena A, Prósper F, Sanmamed MF, Calvo A, Martinez-Climent JA, Pio R.   +22 more
europepmc   +1 more source

Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway. [PDF]

Cancer Lett
Xue Y, Chen T, Ma Z, Pu X, Xu J, Zhai S, Du X, Ji Y, Simon MC, Zhai W, Xue W.   +10 more
europepmc   +1 more source

Targeting Bcl-xL with Navitoclax Effectively Eliminates Senescent Tumor Cells That Appear Following CEP-1347-Induced Differentiation of Glioma Stem Cells. [PDF]

Int J Mol Sci
Takenouchi S, Ito Y, Nakamura K, Nakagawa-Saito Y, Mitobe Y, Togashi K, Suzuki S, Sugai A, Sonoda Y, Kitanaka C, Okada M.   +10 more
europepmc   +1 more source